277 related articles for article (PubMed ID: 21135251)
1. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
Villarroel MC; Rajeshkumar NV; Garrido-Laguna I; De Jesus-Acosta A; Jones S; Maitra A; Hruban RH; Eshleman JR; Klein A; Laheru D; Donehower R; Hidalgo M
Mol Cancer Ther; 2011 Jan; 10(1):3-8. PubMed ID: 21135251
[TBL] [Abstract][Full Text] [Related]
2. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
van der Heijden MS; Brody JR; Dezentje DA; Gallmeier E; Cunningham SC; Swartz MJ; DeMarzo AM; Offerhaus GJ; Isacoff WH; Hruban RH; Kern SE
Clin Cancer Res; 2005 Oct; 11(20):7508-15. PubMed ID: 16243825
[TBL] [Abstract][Full Text] [Related]
3. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
Connor AA; Denroche RE; Jang GH; Timms L; Kalimuthu SN; Selander I; McPherson T; Wilson GW; Chan-Seng-Yue MA; Borozan I; Ferretti V; Grant RC; Lungu IM; Costello E; Greenhalf W; Palmer D; Ghaneh P; Neoptolemos JP; Buchler M; Petersen G; Thayer S; Hollingsworth MA; Sherker A; Durocher D; Dhani N; Hedley D; Serra S; Pollett A; Roehrl MHA; Bavi P; Bartlett JMS; Cleary S; Wilson JM; Alexandrov LB; Moore M; Wouters BG; McPherson JD; Notta F; Stein LD; Gallinger S
JAMA Oncol; 2017 Jun; 3(6):774-783. PubMed ID: 27768182
[TBL] [Abstract][Full Text] [Related]
4. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.
Jones S; Hruban RH; Kamiyama M; Borges M; Zhang X; Parsons DW; Lin JC; Palmisano E; Brune K; Jaffee EM; Iacobuzio-Donahue CA; Maitra A; Parmigiani G; Kern SE; Velculescu VE; Kinzler KW; Vogelstein B; Eshleman JR; Goggins M; Klein AP
Science; 2009 Apr; 324(5924):217. PubMed ID: 19264984
[TBL] [Abstract][Full Text] [Related]
5. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
[TBL] [Abstract][Full Text] [Related]
6. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
7. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
[TBL] [Abstract][Full Text] [Related]
8. PALB2 mutations in familial breast and pancreatic cancer.
Hofstatter EW; Domchek SM; Miron A; Garber J; Wang M; Componeschi K; Boghossian L; Miron PL; Nathanson KL; Tung N
Fam Cancer; 2011 Jun; 10(2):225-31. PubMed ID: 21365267
[TBL] [Abstract][Full Text] [Related]
9. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
Obermeier K; Sachsenweger J; Friedl TW; Pospiech H; Winqvist R; Wiesmüller L
Oncogene; 2016 Jul; 35(29):3796-806. PubMed ID: 26640152
[TBL] [Abstract][Full Text] [Related]
10. [PALB2 as Another Candidate Gene for Genetic Testing in Patients with Hereditary Breast Cancer in Czech Republic].
Janatová M; Borecká M; Soukupová J; Kleiblová P; Stříbrná J; Vočka M; Zemánková P; Panczak A; Veselá K; Souček P; Foretová L; Kleibl Z
Klin Onkol; 2016; 29 Suppl 1():S31-4. PubMed ID: 26691940
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Lohse I; Borgida A; Cao P; Cheung M; Pintilie M; Bianco T; Holter S; Ibrahimov E; Kumareswaran R; Bristow RG; Tsao MS; Gallinger S; Hedley DW
Br J Cancer; 2015 Jul; 113(3):425-32. PubMed ID: 26180923
[TBL] [Abstract][Full Text] [Related]
12. PALB2 mutations in European familial pancreatic cancer families.
Slater EP; Langer P; Niemczyk E; Strauch K; Butler J; Habbe N; Neoptolemos JP; Greenhalf W; Bartsch DK
Clin Genet; 2010 Nov; 78(5):490-4. PubMed ID: 20412113
[TBL] [Abstract][Full Text] [Related]
13. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
Bowman-Colin C; Xia B; Bunting S; Klijn C; Drost R; Bouwman P; Fineman L; Chen X; Culhane AC; Cai H; Rodig SJ; Bronson RT; Jonkers J; Nussenzweig A; Kanellopoulou C; Livingston DM
Proc Natl Acad Sci U S A; 2013 May; 110(21):8632-7. PubMed ID: 23657012
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
[TBL] [Abstract][Full Text] [Related]
15. Assessment of PALB2 as a candidate melanoma susceptibility gene.
Aoude LG; Xu M; Zhao ZZ; Kovacs M; Palmer JM; Johansson P; Symmons J; Trent JM; Martin NG; Montgomery GW; Brown KM; Hayward NK
PLoS One; 2014; 9(6):e100683. PubMed ID: 24949998
[TBL] [Abstract][Full Text] [Related]
16. Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.
Hall JC; Marlow LA; Mathias AC; Dawson LK; Durham WF; Meshaw KA; Mullin RJ; Synnott AJ; Small DL; Krishna M; von Hoff D; Schüler J; Hart SN; Couch FJ; Colon-Otero G; Copland JA
J Transl Med; 2016 May; 14(1):129. PubMed ID: 27165126
[TBL] [Abstract][Full Text] [Related]
17. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
Ghiorzo P; Pensotti V; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bonelli L; Borgonovo G; Bruno W; Gozza A; Gargiulo S; Mastracci L; Nasti S; Palmieri G; Papadia F; Pastorino L; Russo A; Savarino V; Varesco L; Bernard L; Bianchi Scarrà G;
Fam Cancer; 2012 Mar; 11(1):41-7. PubMed ID: 21989927
[TBL] [Abstract][Full Text] [Related]
18. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Rajeshkumar NV; De Oliveira E; Ottenhof N; Watters J; Brooks D; Demuth T; Shumway SD; Mizuarai S; Hirai H; Maitra A; Hidalgo M
Clin Cancer Res; 2011 May; 17(9):2799-806. PubMed ID: 21389100
[TBL] [Abstract][Full Text] [Related]
19. Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.
Park D; Bergin SM; Jones D; Ru P; Koivisto CS; Jeon YJ; Sizemore GM; Kladney RD; Hadjis A; Shakya R; Ludwig T
Cancer Res; 2020 Oct; 80(19):4172-4184. PubMed ID: 32732220
[TBL] [Abstract][Full Text] [Related]
20. PALB2/FANCN: recombining cancer and Fanconi anemia.
Tischkowitz M; Xia B
Cancer Res; 2010 Oct; 70(19):7353-9. PubMed ID: 20858716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]